Sg3 Management, LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Sg3 Management, LLC

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $78,966 - $105,543	-900 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $331,813 - $445,383	4,100 Added 455.56%	5,000 $517,000
Q3 2022 May 15, 2023	SELL	$82.16 - $96.94 $336,856 - $397,454	-4,100 Reduced 82.0%	900 $76,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $73,944 - $87,246	900 New	900 $76,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $304,548 - $380,029	4,100 Added 6.22%	70,000 $5.4 Million
Q4 2021 Feb 15, 2022	BUY	$71.72 - $91.47 $1.05 Million - $1.34 Million	14,600 Added 28.46%	65,900 $5.82 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $1.32 Million - $1.5 Million	17,600 Added 52.23%	51,300 $3.97 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $3.13 Million - $3.51 Million	-41,400 Reduced 55.13%	33,700 $2.81 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $7.61 Million - $9.24 Million	-101,900 Reduced 57.57%	75,100 $5.67 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $11.8 Million - $14.6 Million	162,000 Added 1080.0%	177,000 $15.5 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $14,374 - $26,206	200 Added 1.35%	15,000 $1.14 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $1.18 Million - $1.84 Million	14,800 New	14,800 $1.83 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $1.41 Million - $1.59 Million	-15,000 Closed	0 $0
Q2 2018 Aug 02, 2018	BUY	$76.01 - $99.03 $1.14 Million - $1.49 Million	15,000 New	15,000 $1.41 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.